United States · Platforms & data · Benzinga
Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study

Detailed summary
Lexeo Therapeutics Inc. (NASDAQ:LXEO) on Monday announced positive interim results from its ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.benzinga.com)




